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Abstract
Background: The p53 homologs, p63 and p73, share ,85% amino acid identity in their DNA-binding domains, but they
have distinct biological functions.
Principal Findings: Using chromatin immunoprecipitation and high-resolution tiling arrays covering the human genome,
we identify p73 DNA binding sites on a genome-wide level in ME180 human cervical carcinoma cells. Strikingly, the p73
binding profile is indistinguishable from the previously described binding profile for p63 in the same cells. Moreover, the
p73:p63 binding ratio is similar at all genomic loci tested, suggesting that there are few, if any, targets that are specific for
one of these factors. As assayed by sequential chromatin immunoprecipitation, p63 and p73 co-occupy DNA target sites in
vivo, suggesting that p63 and p73 bind primarily as heterotetrameric complexes in ME180 cells.
Conclusions: The observation that p63 and p73 associate with the same genomic targets suggest that their distinct
biological functions are due to cell-type specific expression and/or protein domains that involve functions other than DNA
binding.
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Introduction
Eukaryotic organisms contain families of DNA-binding tran-
scription factors comprised of structurally related proteins that are
encoded by different genes. Individual members of the family are
often co-expressed in the same cell, and in many cases they can
associate with each other to generate heteromeric transcription
factors. In addition, transcription factor families can exhibit cross-
regulation, in which one family member affects the expression
and/or function of another family member. In general, individual
transcription factors within the family have both distinct and
overlapping biological functions.
An important transcription factor family in mammalian cells
includes the p53 tumor suppressor and two other proteins, p63
and p73, that are strikingly similarity to each other and less similar
to p53 [1,2]. p63 and p73 share,85% amino acid identity in their
DNA binding domain, and they show strong structural and
sequence similarity in their activation, oligomerization, and
isoform-specific, C-terminal domains. p53 binds its target sites as
a tetramer [3–6], and it is presumed that this is the case for p63
and p73. p63 and p73 exist as stable tetramers, and they interact
efficiently to form heterotetramers [7,8], although the DNA-
binding activity of the heterotetramers has not been tested directly.
Neither p63 nor p73 can form heterotetramers with p53, because
p53 lacks a critical second helix in the tetramerization domain that
is present in p63 and p73 [7,8]. The various family members can
co-exist in the same cell, and they exhibit cross-regulation [9–12].
In addition, p63 and p73 can transcriptionally regulate genes
involved in DNA repair [13].
Despite the very high degree of similarity between p63 and p73,
mouse knockout models reveal distinct and non-redundant
physiological roles. p63-deficiency is associated with severe defects
in epithelial development [14–16] and DNA damage responses in
the female germline [17]. In contrast, p73 is implicated in various
biological pathways including neurogenesis, inflammation, sensory
pathways, and osteoblastic differentiation [18,19] as well as
genomic stability and tumor suppression [20]. The molecular
basis for these distinct physiological roles is unknown.
There are multiple explanations, not mutually exclusive, for
how two highly related members of the same protein family can
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have distinct biological functions. First, differences in tissue- and
cell type-specific expression patterns can underlie distinct biolog-
ical functions, even if the proteins are functionally equivalent.
Differences in expression patterns might involve some or all of the
structurally distinct isoforms that arise via alternative splicing,
promoter usage, or 39 end formation. Second, the two proteins can
have distinct target specificities in vivo, either due to subtle
differences in their DNA-binding domains and/or to differences in
cooperative interactions with other DNA-binding proteins. Third,
the two proteins can have functionally distinct domains that
differentially mediate transcriptional activation or repression,
interactions with co-activators or co-repressors, or interactions
with other regulatory proteins. In cases where the proteins
themselves are functionally distinct, the differences could be
intrinsic to the protein sequence and/or reflect differences in
phosphorylation or other post-translational modifications.
The in vivo binding behavior of highly related transcription
factors in the same cells has rarely been examined in a global,
unbiased manner. In the case of the ETS family of transcription
factors, analysis of in vivo binding using genome-wide promoter
microarrays revealed redundant and specific occupancy by
individual members of the family [21]. Comparison of Stat5a
and Stat5b, demonstrated that these highly homologous factors
bind the same sites in vivo, albeit with different kinetics that may
underlie differences in Stat5 biology [22]. A comparison of E2F
family members in normal and tumor cells revealed very similar
DNA-binding profiles in some cell types but not others [23].
In previous work, we used tiled microarrays covering the human
genome to identify,5800 target sites for p63 in ME180, a cervical
carcinoma cell line [24]. Here, we generate a DNA-binding profile
of p73 in the same cells, thereby permitting a comparison of its in
vivo target specificity to that of p63. We show that the p73 and p63
binding profiles are indistinguishable, with a similar p73:p63
binding ratio at essentially all genomic loci. Furthermore, we show
that p63 and p73 co-occupy DNA target sites in vivo, suggesting
that p63 and p73 bind primarily as heteromeric complexes. The
observation that p63 and p73 directly associate with the same set
of genomic targets suggests that their distinct biological functions
are due to cell-type specific expression and/or protein domains
that involve functions other than intrinsic or cooperative DNA
binding to target sites.
Materials and Methods
Chromatin immunoprecipitation (ChIP)
ME180 cells were grown in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% Fetal Bovine Serum. Chroma-
tin immunoprecipitation was performed with a mouse monoclonal
antibody to p73 (11C12), essentially as described previously [24].
As assayed by Western blotting, this antibody interacts with p73,
but shows no detectable cross-reactivity with recombinant p63
(Figure S1). Input and eluted material was treated with Pronase
(1.5 mg/ml) for 2 hrs at 42uC and de-crosslinked by heating for
12 hours at 65uC. The samples were then purified using column
purification (Qiagen PCR Purification kit) per manufacturer’s
instructions.
Sequential CHIP
These were performed essentially as described in [25]. Briefly,
chromatin from ,36108 cells was immunoprecipitated with the
4A4 anti-p63 or 11C12 anti-p73 antibodies as described above.
10% of the eluted material was removed, de-crosslinked, and
designated ‘‘1st IP.’’ The remaining eluate was incubated with
antibody-coupled protein A/G sepharose beads (11C12 for 4A4
1st IP; 4A4 for 11C12 1st IP), BSA (5 mg/ml), phage lambda DNA
(25 mg/ml), and E. coli tRNA (50 mg/ml) in a total volume of 2 ml
IP dilution buffer (approximately 10-fold dilution of eluate).
Washes and elution were performed as described above, and
eluted samples designated ‘‘2nd IP.’’ Precleared chromatin from
the 1st IP was used as ‘‘input’’ DNA for both 1st and 2nd IP
samples.
Random primer amplification
Input and ChIP DNA was amplified by four rounds of primer
extension (Round A) with random primers (GTTTCCCAGT-
CACGGTCNNNNNNNNN), using the following cycling condi-
tions: 95uC, 4 min; 10uC, 5 min; +27uC at 1uC per 20 sec; 37uC,
8 min. Round A material was purified using column purification
(Qiagen PCR Purification kit) and PCR amplified with primer
B(GTTTCCCAGTCACGGTC). PCR program used was: 95uC,
3 min; followed by 30 cycles of 95uC, 30 sec; 40uC, 45 sec; 50uC,
45 sec, 72uC, 1 min; and a final extension at 72uC for 10 min.
The samples were then purified using column purification (Qiagen
PCR Purification kit) and ready for array hybridization protocols.
Tiling array platform and generation of p73 binding sites
The high density, tiled whole genome arrays manufactured by
Affymetrix covers essentially most of the non-repetitive DNA
sequences of the human genome with (on average) one
oligonucleotide pair every 35 bp. There are 7 chips in a full
genome set and approximately 3,200,000 probe sets per chip (PM
probes only). Array data from three biological replicates were
scaled to target intensity of 500 and quantile normalized using
Affymetrix Tiling Analysis Software (Version 1.1.02). A binding p-
value was then determined for each genomic position by Wilcoxon
rank sum test and binding sites were generated from those more
significant than specified thresholds with a maximum gap of 500
and minimum run of 350. For every binding site, a binding
enrichment score was computed from a smoothed ‘‘peak’’
estimator using the five genomic positions with the highest binding
p-values (in the form of -10logP) within the region and one-step
Tukey’s biweight alogorithm. Data for p73 binding is stored at
GEO (GSE18650).
qPCR validation
qPCR was performed essentially as described previously [24],
using an Applied Biosystems 7300 sequence detector for SYBR
green fluorescence. The PCR program was: 95uC 10 min,
followed by 40 cycles of 95uC, 30 sec, 60uC, 45 sec; 72uC,
1 min. Fold enrichment for a genomic region was determined
relative to a non-enriched region (exon 3 of the histone H3 gene).
The formula used was: fold enrichment = 1.92(DCTexpt-DCTref)
where DCT is the cycle threshold (Ct) difference between ChIP
DNA and input material, calculated for experimental and
reference regions, and 1.9 is the mean primer slope. For each
site, we calculated the occupancy units defined as the fold
enrichment value minus background (H3 reference value set to 1).
Based on our previous observations of p63 occupancy for various
control negative regions [24], we defined validated targets as those
regions showing greater than 2.5 occupancy units by qPCR as the
negative controls were consistently below this cutoff. For
‘‘marginal’’ targets (i.e. 3 occupancy units or less), we required
that at least 2 of the 3 replicates give greater than 2.5 occupancy
units to avoid artificial inflation by a single replicate. This
additional criterion was imposed because qPCR values for the p73
samples tended to be more variable than those for p63, likely due
to the lower amounts of immunoprecipitated DNA.
p73 Genomic Binding Profile
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De novo motif discovery
For every binding site, we retrieved repeat-masked sequence
and used de novo motif discovery algorithm MEME [26] to look for
shared sequence motifs. MEME was run with the command line
options ‘‘-mod oops -nmotifs 10 -evt 0.00001 –revcomp’’. The
background frequency was taken from the repeat-masked genome:
A/T=0.6 and C/G=0.4.
Sequence conservation analysis
Based on the multiz-8-way alignments for human, chimp,
mouse, rat, dog, chicken, fugu and zebrafish [27], we generated
overlaid versions of the human genome with corresponding
sequences from the other seven species. In cases of more than one
multiple alignment for a given human region (e.g., with different
indels), we selected the one with the best alignment score.
Percentage of sequence identity was calculated by counting the
proportion of nucleotides in the p73-bound sequences with exact
matches in the overlaid genome. Statistical significance was
assessed with 1000 randomly sampled groups of the same number
of sequences of the same length from the same chromosomes as
p73 binding sites.
Analysis of protein expression
Immunoblotting was performed with the 4A4 anti-p63 and
11C12 anti-p73 antibodies using standard procedures. Briefly,
proteins were separated by SDS-PAGE, transferred to nitrocellu-
lose membrane, blocked in 5% milk (in Tris-buffered saline with
0.05% Tween-20, TBST), and incubated with primary antibody
followed by a horseradish peroxidase conjugated anti-mouse
secondary (Jackson ImmunoResearch Laboratories). Chemilumi-
nescent detection was performed with the SuperSignal Pico
Chemiluminescent Substrate (Pierce) according to manufacturer’s
instructions.
Results
Mapping and verification of p73 binding sites
Chromatin from ME180 cells was immunoprecipitated with an
anti-p73 monoclonal antibody (11C12) that shows no detectable
cross-reactivity with p63 (Figure S1). The immunoprecipated
DNA was hybridized to the Affymetrix Human Tiling 2.0R array
set, interrogating the non-repetitive sequences of the entire human
genome. Data from three biological replicates were combined, and
we identified 488 p73 sites at a significance threshold of P#1025,
the same cut-off used for the p63 analysis previously described
[24]. The number of p73 binding sites is considerably fewer than
the 5800 p63 sites identified in the same manner, but this may
reflect the relative expression levels of the two proteins. In this
regard, p63 is more abundant than p73 in squamous epithelial
cells [28].
We used ‘‘real-time,’’ quantitative polymerase chain reaction
(qPCR) to verify p73 enrichment at several targets identified from
the ChIP-Chip experiment. Five of five sites with P#1025 were
verified as ‘‘true positives,’’ defined as showing at least an average
2.5-fold enrichment in three biological replicates, relative to a
negative control region. We also tested regions with lower binding
scores and verified four of five sites for 1025#P#1024, and eight
of nine targets for 1024#P#1023 (Table S1). These results
indicate many p73 sites from the lower stringency cut-offs
represent true p73 binding targets, consistent with the notion that
transcription factor binding affinities in vivo represent a continuum,
rather than simple presence or absence of binding [29,30].
Nevertheless, to facilitate comparisons with p63 data, we chose the
P#1025 cutoff for most of our subsequent analyses.
Many p73 binding sites in ME180 are located in the vicinity of
annotated, full-length transcripts, and they exhibit a preference for
the 59-ends of genes, with 8.4% and 22.4% of the 488 sites
(P#1025) located within 1 kb and 5 kb upstream of the
transcriptional start, respectively. p73 binding sites included
previously reported p73 targets, such as the PUMA, mdm2, and
p63 genes, and they show strong evolutionary conservation
(Fig. 1A). The consensus motif derived from the identified p73
target sites is very similar to the motif for p53 and indistinguishable
from the p63 response element in ME180 cells (Fig. 1B)[24].
However, this motif occurs numerous times in the mammalian
genome, and it is a poor predictor of where the proteins actually
bind in vivo and hence whether p63 and p73 have similar genomic
DNA-binding profiles [24].
p63 and p73 have indistinguishable DNA binding profiles
in ME180 cells
Comparison of the p73 binding profile with the previously
described p63 binding profile [24] reveals a striking overlap
between p63 and p73 binding sites in ME180 cells. Nearly 80% of
p73 targets at a significance threshold of P#1025 overlap with p63
binding sites identified in our previous work (Table S2). The
percentage overlap is above 60% even at the lower stringency cut-
off of P#1024 (for p73), supporting the similarity between p63 and
p73 binding, and a further indication that sites in this range are
bona fide p73 targets. A comparison of p63 and p73 binding
enrichment scores shows a strong correlation (Pearson correla-
tion= 0.414), with p63 generally showing higher scores than p73
(Fig. 2). These observations are reminiscent of p63 binding in the
presence (+) or absence of (2) actinomycin D, where drug
treatment reduces p63 protein levels and association with DNA,
but does not alter binding specificity [24].
Although p63 and p73 have similar DNA binding profiles, the
above analysis does not address the possibility that a subset of
sites are differentially bound by one of the proteins. To examine
this possibility, we used quantitative PCR analysis to determine
the relative occupancy of p63 and p73 at selected p73 targets
that had a range of array-based p63 binding scores (Fig. 3). All
12 sites that were validated for p73 enrichment show clear p63
binding, including sites with p63 binding scores below the 1025
cutoff used previously to define p63 targets [24]. In this regard,
the p73 binding data is useful for identifying true p63 target sites
that were false negatives at the cutoff chosen in the previous
analysis. We also examined putative p73 target sites (i.e. passed
the 1025 cutoff) that had very low levels of p63 occupancy
(P,1022). In all such cases tested, these putative p73-only sites
showed no detectable levels of either p63 or p73, indicating that
these were false positives from the p73 array results. Most
importantly, for all sites tested, the relative occupancy of p63
and p73 appeared similar, with p63 enrichment being
approximately 2–4 fold higher than that of p73 (Fig. 3). Thus,
we could not demonstrate evidence of unique binding sites for
p73 in ME180 cells.
p63 and p73 co-occupancy in vivo
The observation that p73 and p63 have indistinguishable
binding profiles in ME180 cells does not indicate whether these
two factors are simultaneously bound at the same loci. We
therefore used sequential chromatin immunoprecipitation to
determine co-occupancy of p63 and p73 in vivo [25]. Specifically,
we first performed an immunoprecipitation with antibodies for
one factor (i.e. p63 or p73), eluted the protein-DNA complexes,
and then immunoprecipitated the resulting sample with antibodies
for the other factor (i.e. p73 or p63, respectively). If two factors
p73 Genomic Binding Profile
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11572
co-occupy a DNA site, binding enrichment after the sequential
immunoprecipitations should be higher than enrichment observed
in the single immunoprecipitation [25].
For all eight targets tested, co-occupancy of p63 and 73 was
observed when the first immunoprecipitation was performed with
p73 (Fig. 4A). Specifically, the fold-enrichments in the sequential
immunoprecipitations were 2.5–6 fold higher than in the p73
immunoprecipitation. In the reciprocal experiment in which p63-
bound targets were immunoprecipitated first, seven of eight targets
showed increased enrichment upon subsequent immunoprecipita-
tion with p73 (Fig. 4B). In all cases, the increase in fold-enrichment
upon sequential immunoprecipitation was higher when p73-
bound targets were purified first. Indeed, in the one instance
where we could not demonstrate an increase in fold enrichment
upon sequential immunoprecipitation, this occurred only when
p63 is the first factor immunoprecipitated. This asymmetry in
sequential ChIP results indicates that p63 and p73 partially co-
occupy their target sites in vivo [25]. Partial co-occupancy is likely
to be due to the fact that p63 protein levels markedly exceed those
of p73 (see Discussion).
Figure 1. Evolutionary conservation and DNA sequence motif of p73-bound sites in ME180 cells. (A) Evolutionary conservation is
defined as the total percent identities of p73-bound sequences and 1000 groups of randomly selected comparable genomic sequences across
multiple species. Error bars correspond to standard deviation from 1000 randomly sampled groups. (B) The DNA sequence motif for p73 derived de
novo from the genomic binding sites is compared to the motif for p63 [24] and p53. The p73 motif is essentially identical to the p63 response
(CompareACE score = 0.95) [34].
doi:10.1371/journal.pone.0011572.g001
p73 Genomic Binding Profile
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p63 and p73 co-immunoprecipitate in cell-free extracts [28],
presumably because they can form heterotetramers [7,8].
Consistent with this observation, co-immunoprecipitation of p63
and p73 was observed in samples from the first and second
immunoprecipitations used in the sequential ChIP analysis above
(Fig. 5). Thus, it is likely that p63 and p73 have indistinguishable
genomic targets in ME180 cells primarily due to the ability of
these proteins to form DNA-binding heterotetramers.
Discussion
p73 and p63 have indistinguishable genomic targets and
bind as a heteromeric complex in ME180 cells
Several observations indicate that p63 and p73 have indistin-
guishable genomic targets in ME180 cells. First, there is a striking
overlap between p63 and p73 targets (Tables S1 and S2), and a
strong correlation between p63 and 73 binding scores based on the
genome-wide array data (Fig. 2). Second, among the small subset
of target sites that appear from the genome-wide array
experiments to be differentially bound by p63 and p73, we
examined the best candidates for targets that are bound by p73,
but not p63, and found that all tested were either false positives (for
p73) or false negatives (for p63). Thus, most (and perhaps all) sites
that appear to be differentially bound by p73 and p63 are
explained by being false positives or negatives in one of the
analyses. Third, for all loci tested by quantitative PCR, the relative
binding ratio of p63 and p73 is similar. By definition, differential
binding by p63 and p73 to a given target site should result in a
skewed binding ratio when compared to typical target sites. Thus,
our analyses indicate that there are few, if any, target regions that
are differentially bound by p63 and 73, and that any differences in
relative binding by these two proteins among target sites are subtle.
The sequential ChIP experiment demonstrates that p73 and
p63 co-occupy all sites tested, and hence most (and perhaps all)
Figure 2. p63 and p73 have very similar DNA-binding profiles in ME180 cells. (A) Overlap of p63 and p73 binding sites at three different
significance thresholds. p63 binding sites were identified in our previous work [24], and percentages of overlap are expressed with respect to p73
sites. (B) Correlation between p63 and p73 binding enrichment scores, which were defined as described in Methods. p63 scores are plotted as a
moving average (window size = 50).
doi:10.1371/journal.pone.0011572.g002
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genomic targets. Such co-occupancy indicates that p63 and p73
can bind to their targets as heteromeric complexes. As p63 and
p73 form stable heterotetramers in solution [7,8], the observed co-
occupancy strongly suggests that these proteins can bind DNA as
heterotetramers. Formally, we cannot exclude the possibility that
co-occupancy arises from independent binding of p63 and p73 to
distinct sites in close proximity, although this situation is likely to
be rare, especially given that few target sites have multiple copies
of the DNA-binding motif.
The ability of p63 and p73 to bind as heterotetramers provides a
simple explanation for why they have indistinguishable binding
specificites in ME180 cells. However, our experiments do not
indicate that the similar target profiles of p63 and p73 are due
exclusively to binding by heterotetrameric complexes. It is possible
that p63 and p73 homotetramers have similar target specificity to
each other and likely (although not necessarily) to the hetero-
tetrameric complexes.
Numerous genome-wide ChIP experiments reveal that fold-
enrichments for association of a given protein to target sites vary
over a wide range. This indicates that most target sites are not fully
occupied by the transcription factor, and hence that the concentra-
tion of the protein is limiting for binding, except perhaps for the
strongest sites. As a consequence, and as observed in our previous
work on p63 [24], intracellular protein concentration affects fold-
enrichments and hence the number of target sites identified via
thresholding, although it does not affect site specificity. Thus, higher
levels of p63 vs. p73 is likely to explain why the number of identified
p73 target sites appears to be far lower than the number of p63 sites,
even though the two proteins have indistinguishable target specificity.
As p63 and p73 can bind as a heteromeric complex, the
difference in protein levels affects the stoichiometry of the
complexes. As these proteins, like p53, bind as tetramers, p73
will be typically under-represented in hetero-tetramers, and there
should be a significant number of p63 homo-tetramers in ME180
cells. In accord with theoretical considerations of sequential ChIP
experiments [25], we observe that the co-occupancy of p73 and
p63 is partial and that higher fold-enrichments occur when p73 is
immunoprecipitated first.
Biological implications
Mutational analysis in mice indicates that p63 and p73 control
very different physiological processes [1,14–16,19]. Our results
suggest that, in cell types expressing both proteins, p63 and p73
will directly affect the same set of target genes. At such genes, the
target sites will be bound by essentially the same ratio of
heterotetrameric and homotetrameric complexes, with the ratio
being determined by the relative concentrations of p63 and p73
and the DNA-binding activity of the different types of complexes.
The ratio of the various complexes at target sites can be modified
by physiological conditions that affect one or both proteins. In
such cell types, if p73 and p63 have differential functions, these are
unlikely to be due to the selection of target genes, but rather
differences in transcriptional functions (i.e. activation, repression,
or interactions with co-regulatory factors) of the two proteins.
Figure 3. Comparable ratio of p63 and p73 association with target sites. Shown is the average occupancy value from 3 biological replicates.
The ratio of p63 to p73 occupancy at each target site is indicated.
doi:10.1371/journal.pone.0011572.g003
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Figure 4. p63 and p73 co-occupancy in vivo. Sequential chromatin immunoprecipitation (SeqChIP) samples were analyzed by quantitative PCR
(qPCR) for p63 and p73 enrichment at various targets. Shown is the average occupancy value from 3 biological replicates. (A) p63
immunoprecipitation (1st IP) followed by p73 immunoprecipitation (2nd IP). (B) p73 immunoprecipitation (1st IP) followed by p63
immunoprecipitation (2nd IP). The fold-increase (2nd IP over 1st IP) in enrichment after sequential ChIP is indicated.
doi:10.1371/journal.pone.0011572.g004
p73 Genomic Binding Profile
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Other cell types express either p73 or p63, but not both. In such
cell types, phenotypic effects can only be observed when the gene
encoding the expressed protein is mutated. Similarly, if one
protein is much more prevalent than the other, as is the case in
ME180 cells, it is likely that mutation of the more abundant
protein will cause stronger phenotypic effects. Thus, many, and
perhaps most, of the distinct biological functions of p63 and p73
are likely to reflect differences in cell-type-specific expression.
The DNA-binding profiles of p73 and p63 in cell types that
express only one of these proteins are unknown. In such cell types,
it is likely, that p63 and p73 will associate with some sites in
common, but interact differentially with other genomic regions.
However, individual DNA-binding proteins typically have cell-
type specific binding profiles, because binding to chromatin
templates in mammalian cells generally requires cooperative
interactions with other proteins [24]. Such cooperativity could
involve direct protein-protein contact, common interactions with a
third factor, or synergistic recruitment of chromatin-modifying
factors. Thus, it is unclear whether, on their own, p73 and p63
recognize the same set of target genes. Indeed, it remains possible
that p73 and p63 are functionally equivalent proteins, whose
distinct biological functions reflect differences in expression.
Our findings address reports of p63 and p73 antagonism in
head and neck squamous cell carcinomas [28,31,32], which are a
similar cell type to ME180 cervical carcinomas. Specifically,
DNp63 suppresses TAp73 activation of apoptosis target genes,
Puma and Noxa, and it was proposed that p63, which is
overexpressed in these cells, directly competes for binding to
these promoters and blocks p73 occupancy [28]. Our results
invalidate the notion that p63 and p73 DNA binding is mutually
exclusive. Instead, they suggest that this reflects competition
between p63 homotetramers, p73 heterotetramers, or p63/p73
heterotetramers that have different transcriptional activities.
Lastly, our results are relevant to numerous studies reporting
imbalances of p63 and p73 isoforms in cancer [33]. In particular,
apparent roles of p63 and p73 will be strongly influenced by the
relative levels of these two family members, as well as the specific
isoforms of each protein.
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